A profile on the Truenat assays for the detection of pulmonary tuberculosis and rifampicin resistance
- 18 January 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 26 (2) , 101-112
Abstract
Early diagnosis and treatment initiation are essential to prevent ongoing tuberculosis (TB) transmission and reduce the disease burden. Smear microscopy, which is widely used test for diagnosis has limited sensitivity and does not detect rifampicin resistance. Truenat is a portable, battery-operated, chip-based test that can be placed in peripheral laboratories, serving as a point-of-care test. It also detects rifampicin resistance, which is crucial in the management of TB. Our review comprehensively covers the functionality and workflow of the Truenat MTB assay, in addition to its cost-effectiveness and diagnostic accuracy, based on recent evidence. We also discuss the merits and drawbacks of alternative diagnostic tests available for detecting TB and rifampicin resistance. Truenat assays are rapid molecular tests that revolutionized TB diagnosis, moving toward peripheral testing. Evidence indicates that the Truenat MTB Plus performs better than the original Truenat MTB, with an approximate LOD of 30 CFU/ml. The 2025 WHO guidelines rely exclusively on data from Truenat MTB Plus. We need larger studies on the newer Truenat MTB Ultima to evaluate its performance on tongue swabs. Additionally, data on the accuracy of Truenat MTB in children remains scarce, emphasizing the importance of further research in this group. Evidence regarding its accuracy in detecting rifampicin resistance is also limited, requiring larger studies and technological advancements. Truenat MTB will remain crucial in the fight to eliminate TB in the future.Keywords
This publication has 39 references indexed in Scilit:
- Diagnostic accuracy of truenat MTB plus for the detection of pulmonary and extrapulmonary tuberculosisIndian Journal of Medical Microbiology, 2024
- Utilization of Truenat chips in defining XDR, pre-XDR and MDR in tuberculous meningitisTuberculosis, 2024
- Expedited diagnosis of pediatric tuberculosis using Truenat MTB-Rif Dx and GeneXpert MTB/RIFScientific Reports, 2023
- Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adultsCochrane Database of Systematic Reviews, 2023
- Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosisCochrane Database of Systematic Reviews, 2021
- Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosisMolecular Biology Reports, 2020
- Tuberculosis in ChildrenPediatric Clinics of North America, 2017
- Comparison of sputum collection methods for tuberculosis diagnosis: a systematic review and pairwise and network meta-analysisThe Lancet Global Health, 2017
- Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trialThe Lancet, 2014
- New specimens and laboratory diagnostics for childhood pulmonary TB: progress and prospectsPaediatric Respiratory Reviews, 2011